Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic enrols US patients in ENDEAVOR IV trial:

This article was originally published in Clinica

Executive Summary

Medtronic has begun enrolling patients into ENDEAVOR IV, the final phase of a clinical trial programme that will be used to support a US marketing application for its ABT-578-eluting stent, Endeavor. ENDEAVOR IV is a randomised, single-blind trial comparing Endeavor's safety and efficacy with Boston Scientific's market leading drug-eluting stent, Taxus, a paclitaxel-coated device. The study will include around 1,548 patients and will be performed at around 80 centres in the US and Canada. Its primary endpoint is target vessel failure at nine months.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT054859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel